Posted on 24 January 2013.
Newly approved oral medication slows rheumatoid arthritis joint damage
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month interim analysis of the …
Full News here – Read more on EurekAlert (press release)